The HGF/c-met receptor system under pathological conditions

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 12, Issue 2, 2012, Pages 122-129

  Taniyama, Yoshiaki ^a,b   Azuma, Junya ^a,b   Iekushi, Kazuma ^a,b   Sanada, Fumihiro ^a   Iwabayashi, Masaaki ^a   Kusunoki, Hiroshi ^a   Okayama, Keita ^a   Otsu, Rei ^a   Rakugi, Hiromi ^b   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; C met; Epithelial growth factor receptor (EGFR); Fibroblast growth factor (FGF); Fibrosis; Gene therapy; Hepatocyte growth factor (HGF); Peripheral artery disease (PAD); PTEN; Senescence; TGF beta; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOTENSIN II; ANTIFIBROTIC AGENT; ANTIOXIDANT; ARGININE; BEPERMINOGENE PERPLASMID; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LIPOPROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROLINE; PROTEIN; PROTEIN KINASE B; PROTEIN PHOSPHATASE AND TENSIN HOMOLOG; PROTEIN SH3; PROTEIN TYROSINE PHOSPHATASE SHP; RAC1 PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL GROWTH; CLINICAL TRIAL (TOPIC); CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; ENDOCYTOSIS; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENESCENCE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SPECIES TRANSLOCATION; VASCULAR SMOOTH MUSCLE;

EID: 84860431609     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/187152212800389030     Document Type: Article

References (61)

1. Nakamura, T.; Nishizawa, T.; Hagiya M.; Seki, T.; Shimonishi, M.; Sugimura, A.; Tashiro, K.; Shimizu, S. Molecular cloning and expression of human hepatocyte growth factor. Nature, 1989, 342(6248), 440-443.
2. Uehara, Y.; Minowa, O.; Mori, C.; Shiota, K.; Kuno, J.; Noda, T.; Kitamura, N. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature, 1995, 373(6516), 702-705.
3. Taniyama, Y.; Takeya, Y.; Azuma, J.; Iekushi, K.; Sanada, F.; Kusunoki, H.; Okayama, K.; Koibuchi, N.; Rakugi, H.; Morishita, R. HGF as angiogenic factor and therapeutic approach. Curr. Sign. Transd. Ther., 2011, 6, 221-227.
4. Nakamura, Y.; Morishita, R.; Nakamura, S.; Aoki, M.; Moriguchi, A.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension, 1996, 28(3), 409-413.
5. Nakamura, Y.; Morishita, R.; Higaki, J.; Kida, I.; Aoki, M.; Moriguchi, A.; Yamada, K.; Hayashi, S.; Yo, Y.; Nakano, H.; Matsumoto, K.; Nakamura, T.; Ogihara, T. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J. Hypertens., 1996, 14(9), 1067-1072.
6. Morishita, R.; Nakamura, S.; Nakamura, Y.; Aoki, M.; Moriguchi, A.; Kida, I.; Yo, Y.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes, 1997, 46(1), 138-142.
7. Nakagami, H.; Morishita, R.; Yamamoto, K.; Yoshimura, S.I.; Taniyama, Y.; Aoki, M.; Matsubara, H.; Kim, S.; Kaneda, Y.; Ogihara, T. Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes, 2001, 50(6), 1472-1481.
8. Ponzetto, C.; Bardelli, A.; Zhen, Z.; Maina, F.; dalla Zonca, P.; Giordano, S.; Graziani, A.; Panayotou, G.; Comoglio, P.M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell, 1994, 77(2), 261-271.
9. Yo, Y.; Morishita, R.; Nakamura, S.; Tomita, N.; Yamamoto, K.; Moriguchi, A.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apoptotic action of HGF on epithelial cells. Kidney Int., 1998, 54(4), 1128-1138.
10. Yamamoto, K.; Morishita, R.; Hayashi, S.; Matsushita, H.; Nakagami, H.; Moriguchi, A.; Matsumoto, K.; Nakamura, T.; Kaneda, Y.; Ogihara, T. Contribution of Bcl-2, but not Bcl-xL and Bax, to antiapoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension, 2001, 37(5), 1341-1348.
11. Ridley, A.J.; Comoglio, P.M.; Hall, A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol. Cell Biol., 1995, 15(2), 1110-1122.
12. Rosen, E.M.; Nigam, S.K.; Goldberg, I.D. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J. Cell Biol., 1994, 127(6), 1783-1787.
13. Takaishi, K.; Sasaki, T.; Kato, M.; Yamochi, W.; Kuroda, S.; Nakamura, T.; Takeichi, M.; Takai, Y. Involvement of Rho p21 small GTP-binding protein and its regulator in the HGF-induced cell motility. Oncogene, 1994, 9(1), 273-279.
14. Nakagami, H.; Morishita, R.; Yamamoto, K.; Taniyama, Y.; Aoki, M.; Kim, S.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. J. Hypertens., 2000, 18(10), 1411-1420.
15. Nakamura, Y.; Morishita, R.; Higaki, J.; Kida, I.; Aoki, M.; Moriguchi, A.; Yamada, K.; Hayashi, S.; Yo, Y.; Matsumoto, K.; Nakamura, T.; Ogihara, T. Expression of local hepatocyte growth factor system in vascular tissues. Biochem. Biophys. Res. Commun., 1995, 215(1), 483-488.
16. Taniyama, Y.; Morishita, R.; Aoki, M.; Nakagami, H.; Yamamoto, K.; Yamazaki, K.; Matsumoto, K.; Nakamura, T.; Kaneda, Y.; Ogihara, T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 2001, 8(3), 181-189.
17. Taniyama, Y.; Morishita, R.; Hiraoka, K.; Aoki, M.; Nakagami, H.; Yamasaki, K.; Matsumoto, K.; Nakamura, T.; Kaneda, Y.; Ogihara, T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation, 2001, 104(19), 2344-2350.
18. Taniyama, Y.; Tachibana, K.; Hiraoka, K.; Aoki, M.; Yamamoto, S.; Matsumoto, K.; Nakamura, T.; Ogihara, T.; Kaneda, Y.; Morishita, R. Development of safe and efficient novel non viral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther., 2002, 9(6), 372-380.
19. Azuma, J.; Taniyama, Y.; Takeya, Y.; Iekushi, K.; Aoki, M.; Dosaka, N.; Matsumoto, K.; Nakamura, T.; Ogihara, T.; Morishita, R. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther., 2006, 13(16), 1206-1213.
20. Sanada, F.; Taniyama, Y.; Iekushi, K.; Azuma, J.; Okayama, K.; Kusunoki, H.; Koibuchi, N.; Doi, T.; Aizawa, Y.; Morishita, R. Negative action of hepatocyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ. Res., 2009, 105(7), 667-675.
21. Van Belle, E.; Witzenbichler, B.; Chen, D.; Silver, M.; Chang, L.; Schwall, R.; Isner, J.M. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation, 1998, 97(4), 381-390.
22. Hayashi, S.; Morishita, R.; Nakamura, S.; Yamamoto, K.; Moriguchi, A.; Nagano, T.; Taiji, M.; Noguchi, H.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation, 1999, 100(19), 301-308.
23. Morishita, R.; Nakamura, S.; Hayashi, S.; Taniyama, Y.; Moriguchi, A.; Nagano, T.; Taiji, M.; Noguchi, H.; Takeshita, S.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension, 1999, 33, 1379-1384.
24. Silvagno, F.; Follenzi, A.; Arese, M.; Prat, M.; Giraudo, E.; Gaudino, G.; Camussi, G.; Comoglio, P.M.; Bussolino, F. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1857-1865.
25. Ono, K.; Matsumori, A.; Shioi, T.; Furukawa, Y.; Sasayama, S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation, 1997, 95, 2552-2558.
26. Morishita, R.; Sakaki, M.; Yamamoto, K.; Iguchi, S.; Aoki, M.; Yamasaki, K.; Matsumoto, K.; Nakamura, T.; Lawn, R.; Ogihara, T.; Kaneda, Y. Impairment of collateral formation in lipoprotein(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation, 2002, 105(6), 1491-1496.
27. Morishita, R.; Aoki, M.; Hashiya, N.; Makino, H.; Yamasaki, K.; Azuma, J.; Sawa, Y.; Matsuda, H.; Kaneda, Y.; Ogihara, T. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension, 2004, 44(2), 203-209.
28. Morishita, R.; Makino, H.; Aoki, M.; Hashiya, N.; Yamasaki, K.; Azuma, J.; Taniyama, Y.; Sawa, Y.; Kaneda, Y.; Ogihara, T. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler. Thromb. Vasc. Biol., 2011, 31(3), 713-720.
29. Shigematsu, H.; Yasuda, K.; Iwai, T.; Sasajima, T.; Ishimaru, S.; Ohashi, Y.; Yamaguchi, T.; Ogihara, T.; Morishita, R. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther., 2010, 17(9), 1152-1161.
30. Rajagopalan, S.; Mohler, E.R., Lederman, R.J.; Mendelsohn, F.O.; Saucedo, J.F.; Goldman, C.K.; Blebea, J.; Macko, J.; Kessler, P.D.; Rasmussen, H.S.; Annex, B.H. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation, 2003, 108(16), 1933-1938.
31. Powell, R.J.; Simons, M.; Mendelsohn, F.O.; Daniel, G.; Henry, T.D.; Koga, M.; Morishita, R.; Annex, B.H. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation, 2008, 118(1), 58-65.
32. Nakagami, H.; Morishita, R.; Yamamoto, K.; Taniyama, Y.; Aoki, M.; Matsumoto, K.; Nakamura, T.; Kaneda, Y.; Horiuchi, M.; Ogihara, T. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension, 2001, 37(2), 581-586.
33. Sanada, F.; Taniyama, Y.; Azuma, J.; Iekushi, K.; Dosaka, N.; Yokoi, T.; Koibuchi, N.; Kusunoki, H.; Aizawa, Y.; Morishita, R. Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. Hypertension, 2009, 53(1), 77-82.
34. Vasa, M.; Fichtlscherer, S.; Aicher, A.; Adler, K.; Urbich, C.; Martin, H.; Zeiher, A.M.; Dimmeler, S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res., 2001, 89(1), E1-7.
35. Hill, J.M.; Zalos, G.; Halcox, J.P.; Schenke, W.H.; Waclawiw, M.A.; Quyyumi, A.A.; Finkel, T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med., 2003, 348(7), 593-600.
36. Yu, Y.; Fukuda, N.; Yao, E.H.; Matsumoto, T.; Kobayashi, N.; Suzuki, R.; Tahira, Y.; Ueno, T.; Matsumoto, K. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am. J. Hypertens., 2008, 21(1), 72-77.
37. Tepper, O.M.; Galiano, R.D.; Capla, J.M.; Kalka, C.; Gagne, P.J.; Jacobowitz, G.R.; Levine, J.P.; Gurtner, G.C. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation., 2002, 106(22), 2781-2786.
38. Pesesse, X.; Deleu, S.; De Smedt, F.; Drayer, L.; Erneux, C. Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. Biochem. Biophys. Res. Commun., 1997, 239(3), 697-700.
39. Vandenbroere, I.; Paternotte, N.; Dumont, J.E.; Erneux, C.; Pirson, I. The c-Cbl-associated protein and c-Cbl are two new partners of the SH2-containing inositol polyphosphate 5-phosphatase SHIP2. Biochem. Biophys. Res. Commun., 2003, 300(2), 494-500.
40. Prasad, N.K.; Decker, S.J. SH2-containing 5'-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor. J. Biol. Chem., 2005, 280(13), 13129-13136.
41. Soubeyran, P.; Kowanetz, K.; Szymkiewicz, I.; Langdon, W.Y.; Dikic, I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature., 2002, 416(6877), 183-187.
42. Kowanetz, K.; Szymkiewicz, I.; Haglund, K.; Kowanetz, M.; Husnjak, K.; Taylor, J.D.; Soubeyran, P.; Engstrom, U.; Ladbury, J.E.; Dikic, I. Identification of a novel proline-arginine motif involved in CIN85-dependent clustering of Cbl and down-regulation of epidermal growth factor receptors. J. Biol. Chem., 2003, 278, 39735-39746.
43. Kowanetz, K.; Husnjak, K.; Holler, D.; Kowanetz, M.; Soubeyran, P.; Hirsch, D.; Schmidt, M.H.; Pavelic, K.; De Camilli, P.; Randazzo, P.A.; Dikic, I. CIN85 associates with multiple effectors controlling intracellular trafficking of epidermal growth factor receptors. Mol. Biol. Cell., 2004, 15(7), 3155-3166.
44. Taniyama, Y.; Morishita, R.; Aoki, M.; Hiraoka, K.; Yamasaki, K.; Hashiya, N.; Matsumoto, K.; Nakamura, T.; Kaneda, Y.; Ogihara, T. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension, 2002, 40(1), 47-53.
45. Taniyama, Y.; Morishita, R.; Nakagami, H.; Moriguchi, A.; Sakonjo, H.; Shokei, K.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation, 2000, 102(2), 246-52.
46. Okayama, K.; Azuma, J.; Dosaka, N.; Iekushi, K.; Sanada, F.; Kusunoki, H.; Iwabayashi, M.; Rakugi, H.; Taniyama, Y.; Morishita, R. Hepatocyte growth factor reduces cardiac fibrosis by Inhibiting endothelial-mesenchymal transition. Hypertension, 2012, [Epub ahead of print].
47. Iekushi, K.; Taniyama, Y.; Azuma, J.; Sanada, F.; Kusunoki, H.; Yokoi, T.; Koibuchi, N.; Okayama, K.; Rakugi, H.; Morishita, R. Hepatocyte growth factor attenuates renal fibrosis through TGF-beta1 suppression by apoptosis of myofibroblasts. J. Hypertens., 2010, 28(12), 2454-61.
48. Iekushi, K.; Taniyama, Y.; Kusunoki, H.; Azuma, J.; Sanada, F.; Okayama, K.; Koibuchi, N.; Iwabayashi, M.; Rakugi, H.; Morishita, R. Hepatocyte growth factor attenuates transforming growth factor-{beta}-angiotensin II crosstalk through inhibition of the PTEN/Akt pathway. Hypertension, 2011, 58(2), 190-196.
49. Kusunoki, H.; Taniyama, Y.; Azuma, J.; Iekushi, K.; Sanada, F.; Otsu, R.; Iwabayashi, M.; Okayama, K.; Rakugi, H.; Morishita, R. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-gamma/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. Hypertension, 2012, 59(2), 308-316.
50. Liu, Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am. J. Physiol. Renal. Physiol., 2004, 287(1), F7-16.
51. Dai, C.; Liu, Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J. Am. Soc. Nephrol., 2004, 15(6), 1402-1412.
52. Yang, J.; Dai, C.; Liu, Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am. J. Pathol., 2003, 163(2), 621-632.
53. Bissell, D.M.; Roulot, D.; George, J. Transforming growth factor beta and the liver. Hepatology, 2001, 34(5), 859-867.
54. Kobayashi, E.; Sasamura, H.; Mifune, M.; Shimizu-Hirota, R.; Kuroda, M.; Hayashi, M.; Saruta, T. Hepatocyte growth factor regulates proteoglycan synthesis in interstitial fibroblasts. Kidney Int., 2003, 64(4), 1179-1188.
55. Mizuno, S.; Matsumoto, K.; Li, M.Y.; Nakamura, T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J., 2005, 19(6), 580-582.
56. Nikol, S.; Baumgartner, I.; Van Belle, E.; Diehm, C.; Visona, A.; Capogrossi, M.C.; Ferreira-Maldent, N.; Gallino, A.; Wyatt, M.G.; Wijesinghe, L.D.; Fusari, M.; Stephan, D.; Emmerich, J.; Pompilio, G.; Vermassen, F.; Pham, E.; Grek, V.; Coleman, M.; Meyer, F. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther., 2008, 16(5), 972-978.
57. Kaga, T.; Kawano, H.; Sakaguchi, M.; Nakazawa, T.; Taniyama, Y.; Morishita, R. Hepatocyte growth factor stimulated angiogenesis without inflammation: Differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul. Pharmacol., 2012, [Epub ahead of print].
58. Hashigasako, A.; Machide, M.; Nakamura, T.; Matsumoto, K. Bidirectional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J. Biol. Chem., 2004, 279(25), 26445-26452.
59. Yoshitomi, Y.; Kojima, S.; Umemoto, T.; Kubo, K.; Matsumoto, Y.; Yano, M.; Sugi, T.; Kuramochi, M. Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J. Clin. Endocrinol. Metab., 1999, 84(7), 2425-2428.
60. Nakamura, S.; Morishita, R.; Moriguchi, A.; Yo Y.; Nakamura, Y.; Hayashi, S.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. J. Hypertens., 1998, 16(12), 2019-2026.
61. Nakamura, S.; Moriguchi, A.; Morishita, R.; Aoki, M.; Yo, Y.; Hayashi, S.; Nakano, N.; Katsuya, T.; Nakata, S.; Takami, S.; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara, T. A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension. Biochem. Biophys. Res. Commun., 1998, 242(1), 238-243.